Phospholipase Activity Provides a Simple Test for Systemic Inflammation in Acute and Chronic Disease

INVENTORS • Keith Meyer, Francis Tsao

WARF: P02007US
View U.S. Patent No. 7,579,156 in PDF format.

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a simple, rapid and reproducible assay for systemic inflammation.

OVERVIEW

The inflammatory response plays a role in illnesses from injury to infections to allergies. Initiation of inflammation involves the activation of immune cells that trigger a cascade of events leading to phospholipase A₂ (PLA₂)-involved inflammatory processes.

PLA₂s are enzymes that play a vital role in regulating the production of precursors to a number of pro-inflammatory lipid mediators, including prostaglandins, leukotrienes and platelet activating factor, which in turn exert a wide range of potent physiological effects. Excess production of PLA₂ is associated with diseases such as systemic inflammation, allergy, brain injury, cancer development and metastasis, and cardiovascular disorders. Studying the onset and severity of disorders associated with excess PLA₂ could provide useful diagnostic information as well as information on the efficacy of anti-inflammatory therapies.

THE INVENTION

UW-Madison researchers have developed a fluorescence assay for measuring phospholipase activity, including secretory PLA₂ (sPLA₂) activity. This assay provides a simple, rapid and highly reproducible blood test that can be used to monitor systemic inflammation over an extended period and evaluate the effectiveness of anti-inflammatory therapies.

The assay uses a unique, fluorescently labeled liposome. When a sample containing a phospholipase is added to the liposome, the phospholipase hydrolyzes the phospholipid components of the liposome, causing a detectable change in fluorescence intensity. The degree of change indicates the activity of the phospholipase.

The sample can be compared to a control to determine if an individual has elevated PLA₂ activity, which may indicate a disorder associated with systemic inflammation, such as sepsis, heart disease, cystic fibrosis or chronic obstructive pulmonary disease. The assay...
also can be used to identify agents capable of altering phospholipase activity.

Because the activity of sPLA$_2$ in serum is a critical marker for monitoring the onset and severity of systemic inflammation in patients with sepsis or heart disease, this assay also could be used to create a portable, bedside device for early detection of hyper-inflammation. Such a device could provide accurate, real-time monitoring of changes in fluorescence intensity resulting from changes in sPLA$_2$ activity and may enable early interventions for the prevention of multi-organ failure.

**APPLICATIONS**

- Diagnosis and analysis of sepsis and other disorders
- Evaluation of anti-inflammatory therapies, including dietary interventions
- Identification of phospholipase modulators
- Creation of a portable, bedside device for early detection of hyper-inflammation in patients with sepsis for the prevention of multi-organ failure

**KEY BENEFITS**

- Capable of determining the level of systemic inflammation response in micro-liters of serum
- Substrate and assay standards are stable for months at -20 °C.
- Simple, rapid and highly reproducible
- Capable of monitoring the inflammatory process over a time course of five to six days, rather than three to four hours as seen with traditional inflammatory markers
- Phospholipase activity can be determined based on data collected at a single time point or recorded on a continuous basis.

**ADDITIONAL INFORMATION**

**Publications**

**Tech Fields**
Diagnostic Assays - Other assays

**CONTACT INFORMATION**

For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
Figure 1.
sPLA2-IIA spiked in serum. The sPLA2-IIA activity was determined in human serum spiked with recombinant human sPLA2-IIA. The sPLA2-IIA concentration in the serum was 0.5 ng sPLA2-IIA/1 μl serum. The serum pool was used as control. R² for sPLA2-IIA + serum linearity was 0.9975. The conditions of serum described in this figure can be used for sPLA2 standard preparation. Standard sPLA2 in serum stored at -70°C is stable for more than 2 years.

Figure 1 caption.

Figure 2.
sPLA2 activity in serum from normal healthy volunteers (NV1, NV2, and NV3) and from patients with sepsis and organ failure (P1, P2, and P3).

The assays were conducted in 96-well microplates at 30°C. The sPLA2-IIA activity was determined in Tris buffer containing 10 mM Ca²⁺ and then subtracting from this any background FI changes in the presence of 10 mM Ca²⁺ and 20 mM EGTA. The data is expressed as mean ± SEM (n=3).

Figure 2 caption.